Dodge & Cox Sells 1,225 Shares of Pfizer Inc. (NYSE:PFE)

Dodge & Cox reduced its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 111,560 shares of the biopharmaceutical company’s stock after selling 1,225 shares during the period. Dodge & Cox’s holdings in Pfizer were worth $2,960,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. CacheTech Inc. boosted its position in shares of Pfizer by 22.3% in the 4th quarter. CacheTech Inc. now owns 22,976 shares of the biopharmaceutical company’s stock worth $610,000 after purchasing an additional 4,191 shares during the last quarter. Bridgewater Associates LP increased its stake in shares of Pfizer by 2,211.5% in the 4th quarter. Bridgewater Associates LP now owns 273,839 shares of the biopharmaceutical company’s stock valued at $7,265,000 after acquiring an additional 261,992 shares during the last quarter. M Holdings Securities Inc. acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $2,144,000. Lafayette Investments Inc. boosted its stake in Pfizer by 2.8% during the 4th quarter. Lafayette Investments Inc. now owns 20,758 shares of the biopharmaceutical company’s stock worth $551,000 after acquiring an additional 559 shares during the last quarter. Finally, Schwerin Boyle Capital Management Inc. boosted its position in shares of Pfizer by 0.5% during the fourth quarter. Schwerin Boyle Capital Management Inc. now owns 719,425 shares of the biopharmaceutical company’s stock worth $19,086,000 after purchasing an additional 3,700 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $22.45 on Wednesday. The stock has a market capitalization of $127.30 billion, a PE ratio of 15.92, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a 50 day moving average price of $25.09 and a 200 day moving average price of $26.31. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the business earned $0.10 earnings per share. The firm’s revenue was up 24.7% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group dropped their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday, April 8th. Finally, Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus price target of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.